Skip to content

SEVOFLURANE SOMMINISTRED THROGH ANACONDA VERSUS PROPOFOL + REMIFENTANIL DURING THE SEDATION OF THE CRITICAL PATIENT INTUBATED AND VENTILATED IN THE INTENSIVE CARE UNIT

SEVOFLURANE SOMMINISTRED THROGH ANACONDA VERSUS PROPOFOL + REMIFENTANIL DURING THE SEDATION OF THE CRITICAL PATIENT INTUBATED AND VENTILATED IN THE INTENSIVE CARE UNIT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004695-36-IT
Enrollment
20
Registered
2005-07-15
Start date
2004-12-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SEDATION OF THE CRITICAL PATIENT INTUBATED AND VENTILATED IN ICU

Interventions

Trade Name: SEVORANE*250ML1FL PILFER/PR Product Name: NA Product Code: NA Pharmaceutical Form: Inhalation gas INN or Proposed INN: Sevoflurane CAS Number: 28523-86-6 Concentration unit: IU internation

Sponsors

AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026